How long does bzp stay in system

People generally experience feelings of energy, intensity of feelings, confidence, happiness, openness, closeness to others, dehydration, teeth grinding, feeling hot, and reduced appetite. Too much MDMA can make you confused, anxious, feel like vomiting and even hallucinate. After using people can experience a comedown with feelings of low energy, difficulty sleeping, feeling irritable and mildly depressed, and have difficulty concentrating.

These feelings could last for several days depending on how much you have taken. MDMA makes you feel like moving so there is a risk of overheating, exhaustion, collapsing or having a seizure from overexertion. Drink around ml of water per hour if dancing or active, to help avoid overheating. Make sure you also take breaks to cool down. It is best to be with friends when using MDMA so you have someone to look after you if it is too intense or you begin feeling unwell, disorientated or overwhelmed.

Mixing drugs is always risky because it is hard to predict how one drug will interact with another. MDMA is most often taken orally, which is the safest way to use it. Many participants had reduced the frequency with which they used BZP-party pills due to adverse effects. Potentially risky behaviours identified included taking large doses, mixing BZP-party pills with alcohol and other substances, and driving whilst under the influence of BZP-party pills.

Findings suggest that young people in this study were not suffering excessive or dangerous adverse effects. However, potentially risky use of these products raises the issue of the need for developing harm reduction interventions. A recent phenomenon to have emerged in New Zealand, and one which has proven to be popular amongst young people, is the use of pills containing benzylpiperazine BZP , and sometimes also trifluoromethylphenylpiperazine TFMPP.

They may also contain additional substances such as guarana and vitamins. BZP has been shown to have amphetamine-like effects [ 1 ] and, whilst there is no published literature on the effects of TFMPP on humans, research in rats indicates that is has 'MDMA-like' properties [ 2 ].

At the time of the study , BZP-containing party pills were legally available for sale in a wide range of retail outlets in New Zealand and could also be purchased via the internet and mobile delivery services. A household survey found that one in five people had ever tried BZP-containing party pills, and one in seven had used them in the preceding twelve months.

Their current popularity in New Zealand, particularly amongst young people, may be related to the relatively restricted and expensive illicit market for drugs such as ecstasy.

However, at the time of writing November the New Zealand Government was reviewing the legal status of benzylpiperazine, having announced that it was recommending that the substance be reclassified as a Class C1 drug, thus making it illegal. An announcement regarding any changes in the law is expected in December The legal status of BZP is also currently being reviewed in the UK, whilst several other countries have already banned it, including Australia and the US. There is very limited published data on these substances — both within New Zealand and internationally — particularly with regard to use of the drugs by young people [ 4 ].

The primary aims of this research were to investigate patterns and context of use of BZP-party pills, function of use, positive and negative effects, and knowledge of safe use amongst young people aged 16—24 years. Whilst not reported here, the study also explored aspects of marketing and supply, and views of use by young people amongst 'key experts' employed in associated sectors e.

The aim of this paper is to describe the patterns and context of BZP-party pill use, and positive and negative effects experienced by the young users of BZP-party pills who took part in this study.

A brief synopsis of the data presented here has previously been reported elsewhere [ 4 ] — this paper provides a detailed analysis and interpretation of those results.

Qualitative research methods were adopted for this exploratory study. Data were analysed utilising a general inductive approach [ 5 ], a systematic procedure for analysing qualitative data which draws on grounded theory [ 6 ].

In keeping with the study's youth development approach, the research was also aligned with the six principles i of the Youth Development Strategy Aotearoa YDSA [ 7 ]. Thus, the researchers worked with young people, where possible, throughout the set-up, recruitment and data collection phases ii.

This included training and working with youth 'fieldworkers' who were employed to recruit participants, developing relationships with youth organisations, and consulting young people on the methods used to attract participants and to collect data.

The study was publicised via flyers and cards distributed in party pill retail outlets, bars and clubs, tertiary education campuses, and a range of youth and health organisations and advertisements placed in suitable online and paper-based publications e.

This recruitment approach has shown to be effective in reaching 'hidden' populations, such as drug users [ 8 ]. Inclusion criteria for the study were young people aged 16—24 years old who had used BZP-party pills at least once in the last 12 months, and who were willing to give written, informed consent in order to take part. They were excluded if they, or a close friend or family member, were involved in the manufacture, distribution or retail of BZP-party pills.

Potential participants were able to indicate their interest in taking part in the research either via text or by calling a Freephone number, and were screened over the telephone to determine their eligibility to participate. This proved to be the case with this study, with the vast majority electing to take part with friends.

Interviews and group discussions were semi-structured. The key questions were shaped by the need to explore users' experiences both positive and negative of a new substance, about which little was known — and were developed with input from the project advisory group and piloted prior to the research commencing.

Topics covered included patterns of use e. All respondents provided signed, informed consent and received a movie voucher as a 'thank you' for their contribution to the research. They were held in a range of community locations e. All interviews and group discussions, except one iii , were recorded and transcribed and thematic analysis of the data was undertaken, utilising a general inductive approach [ 5 ].

A selection of transcripts was first read through by the lead researcher and a basic coding frame developed. Data coding was undertaken with the aid of computer-assisted qualitative data analysis software N-VIVO , with two members of the research team coding half the transcripts each.

The coding frame was developed and amended with input from both researchers, where appropriate, during this process. To ensure reliability, the coded data were then read through by both researchers and checked for consistency.

Analysis of the data was undertaken with additional input from two further researchers with different backgrounds, thus adding another dimension to the analysis process. Ten individual interviews, 11 paired interviews and 7 groups range 3—5 respondents were conducted, and comprised a total of 58 young people 28 female and 30 male. The majority of interviews and groups were conducted in two large urban centres in New Zealand.

All but one person had drunk alcohol during the previous six months data missing on one person. Twenty two reported not having smoked cigarettes and 12 reported having used no illegal drugs during this time.

Of those who reported having used illicit drugs, 34 had used cannabis, 30 had used ecstasy, 16 had used LSD lysergic acid diethylamide , four had used nitrous oxide, and three or fewer young people had used 'speed', GHB gammahydroxybutyrate , methamphetamine, 'magic mushrooms', and ketamine. Note: respondents could provide more than one response. Some had used illicit substances prior to BZP-party pills, whereas for others alcohol aside their first experience of drug-taking had involved party pills.

Most were introduced to BZP-party pills by a friend or relative who had used them previously. First use of the substances appears to be a seminal event amongst these young people — not least because it was often a negative experience.

In some cases, this was because it involved taking a large number of pills in combination with alcohol — often on the recommendation of a friend or peer:. First time I took party pills I was She [friend] took me to [name of specialist retailer] and gave me a couple of packets of [name of product].

I had no idea what I'd taken but I trusted her. Afterwards she told me we'd taken three times the recommended dosage. This finding again highlights the role of peers and social networks with regard to initiation into adolescent drug use, and the fact that friends are a trusted source of advice and substances [ 10 - 12 ]. However, as evident in the interview extract above, such advice may be ill-informed or unsafe.

Some young people recalled first time use of BZP-party pills positively, as being an encounter with something exciting and new:.

A couple of mates gave me some [name of product]. They are really weak, but because it was my first time it was fantastic. I danced my arse off all night. The above two interview extracts also demonstrate the context of use of the pills — i. Both have associated risks, including increased likelihood of negative effects in the first example, and potential overheating and dehydration in the second.

A number of respondents had reduced the frequency with which they used BZP-party pills. For most, this was due to the negative side-effects of the products:. I: So you don't take them as much as you used to. Do you want to tell me a little bit about that? R1: It's okay at the time but the next day just kills you. And even at the time it's good but it's never that great like you always kind of feel a bit R1: Yeah, like 3 months, it's not good.

It's all, I don't know, it's relentless. You can't stop it or slow down or anything. Say you're trying to sleep but nah.

R2: Yeah, I haven't thought about it for a while. You know what they say. Bad kind of outweighs the good. Others spoke about life changes that had impacted on their frequency of use e. The data in this section need to be interpreted with caution, as the amount of BZP and TFMPP per pill varies considerably between brands it has been reported that over brands have been available for purchase in New Zealand [ 13 ] ; it is therefore not possible to calculate the actual amount of these chemicals per individual pill or capsule.

Young people's behaviour varied with regard to the number of party pills they were taking on each occasion. Some were only taking one pill, whereas others were taking up to six. Many were taking more than the 'recommended amount' iv on the packaging, with a number of interviewees reporting that they took around two to three pills per occasion on average. Where people were taking more than one pill they often split this amount, and spread it over the course of the BZP-party pill-taking occasion.

However, some people had taken all the pills at once. Again, given the variation in amount of BZP and TFMPP across individual pills and brands, this may mean that young people experience a greater degree of intoxication than anticipated. There was also evidence that some young people titrated their amount against the effects received:. Oh yeah, you don't even think how many you've taken — I just, I'll have like three at first and then if that doesn't last me the night I just take another until I've got the right energy.

Young people generally had a specific pattern of use with regard to amount used — i. This was mostly dependent upon the degree of intoxication they felt comfortable with.

However, the amount used was sometimes varied, depending on the strength of the products being consumed and the context of use e.

Treatment options usually focus on behavioral therapies that help people change the underlying thought patterns that contribute to substance use. Cognitive-behavior therapy, individual counseling, and support groups are approaches that might be utilized in either outpatient or residential settings. Learn the best ways to manage stress and negativity in your life. Dark classics in chemical neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem Neurosci. Meyer JS.

Subst Abuse Rehabil. MDMA and the brain: A short review on the role of neurotransmitters in neurotoxicity. Basic Clin Neurosci. MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol. Althobaiti YS, Sari Y. Alcohol interactions with psychostimulants: An overview of animal and human studies. J Addict Res Ther. Byock I. Taking psychedelics seriously. J Palliat Med. Parrott AC. Drug Alcohol Depend. Asser A, Taba P. Psychostimulants and movement disorders.

Front Neurol. National Institute on Drug Abuse. MDMA Ecstasy abuse research report. Updated September 26, Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. Updated June Your Privacy Rights. To change or withdraw your consent choices for VerywellMind. At any time, you can update your settings through the "EU Privacy" link at the bottom of any page. These choices will be signaled globally to our partners and will not affect browsing data.

Trazodone is licensed in a number of Member States for the treatment of depression and other disorders. The substance 1- 3-chlorophenyl 3-chloropropyl -piperazine mCPCPP is a precursor used in the manufacture of antidepressant drug nefazodone.

BZP and otherpiperazines drug profile September Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances February Aunan, J. Baumann, M. Balmelli, C. Dtsch Med Wochenschr.

Volume , Nos 28—29, pp. Bossong, M. Bye, C. Campbell, H. Council Decision on defining 1-benzylpiperazine BZP as a new psychoactive substance which is to be made subject to control measures and criminal provisions, Council of the European Union, Brussels, 29 February Deprez, N. Elliott, S. Eriksson E. Feuchtl, A. Gee, P. Ghaziuddin, N. Gobbi, M. Maurer, H.